ISRCTN70833965已完成2 期
A phase II double-blind, randomised controlled trial of VEGF inhibitor axitinib monotherapy with early dynamic contrast-enhanced ultrasound monitoring in chemo-refractory third-line metastatic colorectal cancer
Imperial College of Science, Technology and Medicine (UK)0 个研究点目标入组 51 人开始时间: 2013年10月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participants must meet all of the following inclusion criteria to eligible for enrollment into the trial:
- •1. Histologically or cytologically confirmed adenocarcinoma of the colon or rectum with liver metastas(es), at least one of which should not have had any focal therapy including radiofrequency ablation, chemoembolization, ethanol or cryoablation.
- •2. Failed at least two chemotherapy regimens in advanced disease.
- •3. Evidence of unidimensionally measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
- •4. Male and female, 18 years of age or older.
- •5. ECOG performance status of 0 or 1.
- •6. Resolution of all acute toxic effects of prior therapy e.g. radiotherapy or surgical procedure to NCI CTCv4 grade =1.
- •7. Adequate organ function as defined by the following criteria:
- •7.1. Serum aspartate aminotransferase (AST¿ serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine aminotransferase (ALT¿ serum glutamic pyruvic transaminase [SGPT]) =2.5 x upper limit of normal (ULN). For patients with liver metastases, <5 x ULN.
- •7.2. Total serum bilirubin <1.5 x ULN
- •7.3. Serum albumin =3.0 g/dL
- •7.4. Absolute neutrophil count =1500/µL
- •7.5. Platelets =100,000/µL
- •7.6. Haemoglobin =9.0 g/dL
- •7.7. Serum creatinine =1.5 x ULN
- •8. Signed and dated informed consent form
- •9. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- •10. At least 2 weeks since the end of prior systemic treatment (4 weeks for Bevacizumab-containing regimens), radiotherapy, or surgical procedure with resolution of all treatment-related toxicity to NCI CTCAE Version 3.0 grade =1 or back to baseline except for alopecia or hypothyroidism.
- •11. No evidence of pre-existing uncontrolled hypertension as documented by two baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be =140 mmHg, and the baseline diastolic blood pressure readings must be =90 mmHg. Patients whose hypertension is controlled by anti-hypertensive therapies are eligible.
- •12. Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment.
- •13. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment.
排除标准
- •Participants must be excluded if they present with any of the following exclusion criteria:
- •1. Non-exposed to both oxaliplatin and irinotecan FP based cytotoxic chemotherapy (prior pelvic radiation therapy including adjuvant or neoadjuvant chemoradiation therapy for resected rectal cancer is allowed provided it is completed within 4 weeks prior to study entry)
- •2. Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and St John?s wort). Current use or anticipated need for treatment with drugs that are known CYP3A4 inhibitors (i.e., grapefruit juice, ketoconazole, nefazodone, itraconazole, miconazole, erythromycin, clarithromycin, telithromycin, verapamil, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine)
- •3. Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.
- •4. Non-English speaking
- •5. Pregnancy, breastfeeding, or unwillingness/inability to employ an effective method of birth control/contraception to prevent pregnancy during treatment and for up to 3 months after discontinuing study drug if of reproductive potential.
- •6. Hypertension uncontrolled by medication (>150/100 mmHg despite optimal medical therapy).
- •7. Diagnosis of any second malignancy within the last 3 years that is potentially liable to interfere with study outcomes (basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma and hormone-controlled locally advanced prostate cancer that has been adequately treated with no evidence of recurrent disease for 12 months, are allowed)
- •8. Prior surgery or IMP within 4 weeks prior to study entry
- •9. Current treatment within another therapeutic clinical trial.
研究者
相似试验
已完成
2 期
A Phase 2 Double-blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of 10 mcg HXP-GPOVac Vaccine in Healthy VolunteersHealthy male and female subjectsTCTR20220804007The Government Pharmaceutical Organization300
进行中（未招募）
1 期
Saline hypertonic in preschoolers and lung structure as measured by computed tomography.Cystic FibrosisEUCTR2015-004143-39-FRErasmus MC120
进行中（未招募）
1 期
Saline hypertonic in preschoolers and lung structure as measured by computed tomography.Cystic FibrosisEUCTR2015-004143-39-NLErasmus MC120
进行中（未招募）
1 期
Saline hypertonic in preschoolers and lung structure as measured by computed tomography.MedDRA version: 20.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2015-004143-39-ITErasmus MC120
进行中（未招募）
1 期
Saline Hypertonic in Preschoolers with cystic fibrosis and lung structure asmeasured by computedtomography (CT). SHIP-CT study.Cystic fibrosisMedDRA version: 19.1Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-004143-39-DKErasmus MC120